Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.48 |
| ▸ | CHUK | O15111 | 1/20 | 0.48 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.48 |
| ▸ | PRKCG | P05129 | 1/20 | 0.48 |
| ▸ | PRKCB | P05771 | 1/20 | 0.48 |
| ▸ | PRKCA | P17252 | 1/20 | 0.48 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.48 |
| ▸ | PRKCH | P24723 | 1/20 | 0.48 |
| ▸ | PRKCI | P41743 | 1/20 | 0.48 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.48 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.48 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.48 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.48 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.48 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.48 |
| ▸ | AXL | P30530 | 2/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | NOS1 | P29475 | 4/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | METAP2 | P50579 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30861139 | 1.00 | CSNK2A1 (0.48) | CSNK2A1CHUKPRKD3PRKCGPRKCB | |
| SCHEMBL3537413 | 0.80 | BRD4 (0.48) | AXLBRD4NOS1IDO1METAP2 | |
| SCHEMBL31411430 | 0.79 | BRD4 (0.47) | AXLBRD4NOS1IDO1METAP2 | |
| SCHEMBL25799617 | 0.79 | BRD4 (0.47) | AXLBRD4NOS1IDO1METAP2 | |
| SCHEMBL2669701 | 0.79 | BRD4 (0.47) | CSNK2A1CHUKPRKD3PRKCGPRKCB | |
| SCHEMBL1965644 | 0.79 | BRD4 (0.47) | AXLBRD4NOS1IDO1METAP2 | |
| SCHEMBL23043392 | 0.78 | TRPA1 (0.45) | CSNK2A1AXLNOS1IDO1METAP2 | |
| SCHEMBL30959994 | 0.78 | TRPA1 (0.45) | CSNK2A1AXLNOS1IDO1METAP2 | |
| SCHEMBL19304040 | 0.76 | BRD4 (0.44) | AXLBRD4NOS1IDO1METAP2 | |
| SCHEMBL23979717 | 0.76 | BRD4 (0.44) | CSNK2A1CHUKPRKD3PRKCGPRKCB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4680226-A2 | ACYLSULFONAMIDE KAT6A INHIBITORS | Olema Pharmaceuticals, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20260015327-A1 | ACYLSULFONAMIDE KAT6A INHIBITORS | OLEMA PHARMACEUTICALS INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-20250388577-A1 | METTL3 INHIBITORY COMPOUNDS | STORM THERAPEUTICS LTD (GB) | 2025-12-25 | — | — | US | disclosed |
| US-12428379-B2 | Acylsulfonamide KAT6A inhibitors | OLEMA PHARMACEUTICALS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-12358915-B2 | METTL3 inhibitory compounds | STORM Therapeutics Ltd. (GB) | 2025-07-15 | — | — | US | disclosed |
| WO-2025129135-A2 | COMPOSITIONS COMPRISING USP1 INHIBITORS AND METHODS OF USING THE SAME | EIKON THERAPEUTICS, INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| US-20250136553-A1 | ACYLSULFONAMIDE KAT6A INHIBITORS | OLEMA PHARMACEUTICALS, INC. | 2025-05-01 | — | — | US | disclosed |
| EP-4501932-A2 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| EP-3880208-B1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-11-20 | — | — | EP | disclosed |
| WO-2024189598-A2 | ACYLSULFONAMIDE KAT6A INHIBITORS | OLEMA PHARMACEUTICALS, INC. (US) | 2024-09-19 | — | — | WO | disclosed |
| US-20110190335-A1 | NITROGENATED 5-MEMBERED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-04 | — | — | US | disclosed |
| EP-2336128-A1 | Benzoisothiazoles and preparation and uses thereof | Memory Pharmaceuticals Corporation (US) | 2011-06-22 | — | — | EP | disclosed |
| EP-2266983-A1 | NITROGENATED 5-MEMBERED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-12-29 | — | — | EP | disclosed |
| US-20100105677-A1 | INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, AND PREPARATION AND USES THEREOF | XIE WENGE | 2010-04-29 | — | — | US | disclosed |
| US-20090286800-A1 | Glucokinase Activators | TAKEDA SAN DIEGO, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090286800-A1 | Glucokinase Activators | TAKEDA SAN DIEGO, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| WO-2009140624-A2 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. (US) | 2009-11-19 | — | — | WO | disclosed |
| EP-1735306-A2 | INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, AND PREPARATION AND USES THEREOF | Memory Pharmaceuticals Corporation (US) | 2006-12-27 | — | — | EP | disclosed |
| US-20050234095-A1 | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION | 2005-10-20 | — | — | US | disclosed |
| WO-2005092890-A2 | INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, AND PREPARATION AND USES THEREOF | MEMORY PHARMACEUTICALS CORPORATION (US) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12358915-B2 | METTL3 inhibitory compounds | METTL3, METTL16, DIMT1 | CSNK2A1 2384/4885CHUK 414/4885PRKD3 728/4885 |
| US-20250136553-A1 | ACYLSULFONAMIDE KAT6A INHIBITORS | KAT6A, KAT2A, KAT6B | CSNK2A1 69/4885CHUK 365/4885PRKD3 1409/4885 |
| US-12428379-B2 | Acylsulfonamide KAT6A inhibitors | KAT6A, KAT2A, KAT6B | CSNK2A1 69/4885CHUK 365/4885PRKD3 1409/4885 |
| US-20100105677-A1 | INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, AND PREPARATION AND USES THEREOF | CHRNA7, CHRNA5, CHRNA3 | CSNK2A1 1074/4885CHUK 1928/4885PRKD3 2021/4885 |
| US-20090286800-A1 | Glucokinase Activators | GCK, GCKR, GALK1 | CSNK2A1 930/4885CHUK 457/4885PRKD3 997/4885 |
| US-20260015327-A1 | ACYLSULFONAMIDE KAT6A INHIBITORS | KAT6A, KAT2A, KAT6B | CSNK2A1 84/4885CHUK 385/4885PRKD3 1507/4885 |
| US-20250388577-A1 | METTL3 INHIBITORY COMPOUNDS | METTL3, RNMT, TPMT | CSNK2A1 2277/4885CHUK 1066/4885PRKD3 1650/4885 |
| US-20110190335-A1 | NITROGENATED 5-MEMBERED HETEROCYCLIC COMPOUND | GCKR, GCK, SLC5A1 | CSNK2A1 717/4885CHUK 34/4885PRKD3 2799/4885 |
| US-20050234095-A1 | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof | CHRNA7, CHRNA5, CHRNA3 | CSNK2A1 1074/4885CHUK 1928/4885PRKD3 2021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.